Vitrolife AB (publ)
Stockholm Stock Exchange VITR.ST
Vitrolife AB (publ) EBITDA for the year ending December 31, 2023: USD -314.36 M
-
Vitrolife AB (publ) EBITDA for the year ending December 31, 2022 was USD 94.83 M, a 48.61% change year over year.
-
Vitrolife AB (publ) EBITDA for the year ending December 31, 2021 was USD 63.81 M, a 20.03% change year over year.
-
Vitrolife AB (publ) EBITDA for the year ending December 31, 2020 was USD 53.16 M, a -15.94% change year over year.
-
Vitrolife AB (publ) EBITDA for the year ending December 31, 2019 was USD 63.24 M, a 24.74% change year over year.
| Date | EBITDA | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) |
|---|
| CEO | Ms. Bronwyn Brophy O´Connor |
| IPO Date | June 28, 2001 |
| Location | Sweden |
| Headquarters | Gustaf Werners gata 2 |
| Employees | 1,111 |
| Sector | Health Care |
| Industries | |
Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email